[Market Focus] Chaperone Rises on Entry into China with World’s First Inflammasome Inhibitor Platform Technology

Chaperone is showing strong performance. This is interpreted as being influenced by news that the company will officially enter the Chinese market in partnership with a Chinese biotech firm.

As of 9:39 a.m. on the 17th, Chaperone is trading at 3,430 won, up 3.31% from the previous day.

On this day, Chaperone announced that it had signed a memorandum of understanding (MOU) with Ningbo Sansheng Biological Technology (hereafter Sansheng), a leading Chinese biotech company, for the joint development of therapeutics and vaccines based on NanoMab, as well as inflammasome inhibitors. Chaperone stated that, starting with this MOU, it will accelerate its official entry into the Chinese market and continue joint research and development with Sansheng to expedite the global commercialization of new drugs.

Through this MOU, the two companies will jointly develop NanoMab-based therapeutics and vaccines, as well as synthetic drugs targeting inflammatory diseases. They plan to conduct joint research for both veterinary and human disease applications of these new drugs, and will also pursue business operations within China. The two companies aim to strengthen their strategic partnership to achieve commercialization and business expansion in the global market, including China.

Sansheng is a biotech company with a leading position in the development of animal reproductive hormones and new drugs in China. In 2019, it was certified as a National High-Tech Enterprise by the Chinese government, recognizing its advanced technology and growth potential. The company invests approximately 10% of its revenue in research and development (R&D), and is enhancing its new drug development and production capabilities through active collaboration with leading research institutions both in China and abroad.

Chaperone's proprietary NanoMab antibody therapeutic platform is a technology for developing multi-target antibody therapeutics. Compared to conventional antibodies, NanoMab antibodies are only one-tenth the size, offering superior tissue penetration and target diversity, and enabling the development of stable therapeutics in various forms such as bispecific antibodies, trispecific antibodies, and antibody-drug conjugates (ADC). Recently, Chaperone presented research results on the anticancer efficacy and safety of the NanoMab-based bispecific antibody 'Papillicimab' at the American Association for Cancer Research (AACR). In addition, through the publication of various preclinical papers on different pathogens, NanoMab is gaining attention as a next-generation precision immunotherapy technology.

Chaperone possesses the world’s first inflammasome inhibitor platform targeting GPCR19. Its core pipeline includes 'NuGel', an atopic dermatitis treatment, and 'NuSepin', a COVID-19 treatment, both of which demonstrated excellent safety and efficacy in Phase 2 clinical trials, earning recognition for Chaperone’s global clinical capabilities. In particular, NuGel is currently undergoing Phase 2b Part 2 clinical trials with the U.S. FDA, and discussions on technology transfer and joint development with global pharmaceutical companies are actively underway.

NuSepin recently secured excellent safety and efficacy in Phase 2 clinical trials conducted with approval from the European Medicines Agency (EMA), in response to the resurgence of COVID-19 in Greater China and Asia. According to the company, Chaperone’s global clinical references are expected to create synergy through collaboration with Chinese biotech companies that possess global networks.

A Chaperone representative stated, "We were able to sign this MOU because our proprietary inflammasome inhibitor platform and NanoMab antibody development platform were highly evaluated," adding, "Through strategic cooperation with a Chinese biotech company with outstanding new drug development and production capabilities, we expect Chaperone’s innovative therapeutics to enter and be commercialized in the global market more rapidly."